VAXCYTE, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
VAXCYTE, INC. (PCVX) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$604.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-05
- VAXCYTE, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$284.30M.
- VAXCYTE, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$320.62M.
- VAXCYTE, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$246.51M.
- VAXCYTE, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$212.83M.
- VAXCYTE, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$766.63M.
- VAXCYTE, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$463.93M.
- VAXCYTE, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$402.27M.
- VAXCYTE, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$223.49M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$284.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$604.92M 10-Q · filed 2026-08-05 | -$851.43M derived: sum of 3 quarters · filed 2026-08-05 | -$1.06B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$320.62M 10-Q · filed 2026-05-06 | -$567.13M derived: sum of 2 quarters · filed 2026-05-06 | -$779.96M derived: sum of 3 quarters · filed 2026-05-06 | -$946.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$246.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$459.34M derived: sum of 2 quarters · filed 2026-02-24 | -$625.91M derived: sum of 3 quarters · filed 2026-08-05 | -$766.63M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$212.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$379.40M derived: sum of 2 quarters · filed 2026-08-05 | -$520.12M 10-Q · filed 2025-11-04 | -$657.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$166.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$307.29M 10-Q · filed 2026-08-05 | -$444.37M derived: sum of 3 quarters · filed 2026-08-05 | -$547.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$140.72M 10-Q · filed 2026-05-06 | -$277.80M derived: sum of 2 quarters · filed 2026-05-06 | -$380.92M derived: sum of 3 quarters · filed 2026-05-06 | -$509.63M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$137.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$240.20M derived: sum of 2 quarters · filed 2026-02-24 | -$368.91M derived: sum of 3 quarters · filed 2026-02-24 | -$463.93M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$103.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$231.83M derived: sum of 2 quarters · filed 2025-11-04 | -$326.85M 10-Q · filed 2025-11-04 | -$507.65M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$128.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$223.72M 10-Q · filed 2025-08-06 | -$404.52M derived: sum of 3 quarters · filed 2026-02-24 | -$497.19M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$95.02M 10-Q · filed 2025-05-07 | -$275.82M derived: sum of 2 quarters · filed 2026-02-24 | -$368.49M derived: sum of 3 quarters · filed 2026-02-24 | -$436.82M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$180.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$273.46M derived: sum of 2 quarters · filed 2026-02-24 | -$341.80M derived: sum of 3 quarters · filed 2026-02-24 | -$402.27M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$92.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$161.00M derived: sum of 2 quarters · filed 2024-11-05 | -$221.47M 10-Q · filed 2024-11-05 | -$299.51M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$68.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$128.80M 10-Q · filed 2024-08-06 | -$206.85M derived: sum of 3 quarters · filed 2025-02-25 | -$264.77M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$60.46M 10-Q · filed 2024-05-08 | -$138.51M derived: sum of 2 quarters · filed 2025-02-25 | -$196.43M derived: sum of 3 quarters · filed 2025-02-25 | -$244.96M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$78.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$135.97M derived: sum of 2 quarters · filed 2025-02-25 | -$184.50M derived: sum of 3 quarters · filed 2025-02-25 | -$223.49M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$57.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$106.45M derived: sum of 2 quarters · filed 2023-11-06 | -$145.44M 10-Q · filed 2023-11-06 | -$174.00M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$48.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$87.52M 10-Q · filed 2023-08-08 | -$116.08M derived: sum of 3 quarters · filed 2024-02-27 | -$142.70M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$38.99M 10-Q · filed 2023-05-08 | -$67.55M derived: sum of 2 quarters · filed 2024-02-27 | -$94.16M derived: sum of 3 quarters · filed 2024-02-27 | -$117.84M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$28.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$55.18M derived: sum of 2 quarters · filed 2024-02-27 | -$78.86M derived: sum of 3 quarters · filed 2024-02-27 | -$100.08M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$26.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$50.29M derived: sum of 2 quarters · filed 2022-11-07 | -$71.51M 10-Q · filed 2022-11-07 | -$92.25M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$23.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$44.90M 10-Q · filed 2022-08-08 | -$65.64M derived: sum of 3 quarters · filed 2023-02-27 | -$86.65M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$21.22M 10-Q · filed 2022-05-09 | -$41.96M derived: sum of 2 quarters · filed 2023-02-27 | -$62.98M derived: sum of 3 quarters · filed 2023-02-27 | -$83.30M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$20.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$41.76M derived: sum of 2 quarters · filed 2023-02-27 | -$62.08M derived: sum of 3 quarters · filed 2023-02-27 | -$89.22M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$21.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$41.34M derived: sum of 2 quarters · filed 2021-11-10 | -$68.48M 10-Q · filed 2021-11-10 | -$83.10M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$20.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$47.46M 10-Q · filed 2021-08-11 | -$62.08M derived: sum of 3 quarters · filed 2022-02-28 | -$73.40M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$27.14M 10-Q · filed 2021-05-11 | -$41.76M derived: sum of 2 quarters · filed 2022-02-28 | -$53.08M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | -$14.62M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$25.94M derived: sum of 2 quarters · filed 2022-02-28 | -$50.27M 10-K · filed 2022-02-28 | |
| 2019-09-30 | -$11.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$35.65M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | -$24.34M 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | -$29.48M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |